Slide 11
Slide 11 text
Hormone Replacement Therapy:
North American Menopause Society
Position Statement 2022
“In women in the WHI aged 50 to 59 years, CEE plus MPA (average, 5.6 years of use) or
CEE alone (average, 7.2 years of use in women with previous hysterectomy) did not
increase cancer mortality or CV mortality after a median of 18 years’ follow-up compared
with placebo.”
“In women aged 50 to 59 years at randomization, all-cause mortality was significantly
reduced in the pooled trials versus placebo (HR, 0.69; 95% CI, 0.51-0.94). With age groups
combined, breast cancer mortality was reduced in women using CEE alone (HR 0.55; 95%
CI, 0.33-0.92), and Alzheimer disease or dementia mortality was reduced in women using
CEE alone (HR, 0.74; 95% CI, 0.59-0.94) and in the pooled trials (HR, 0.85; 95% CI, 0.74-0.98)
after a median of 18 years’ follow-up.”
https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-
position-statement.pdf